(Q37762482)

22 August 2017

1 reference

title

Abacavir and cardiovascular risk: reviewing the evidence (English)

1 reference

22 August 2017

1 reference

1 reference

Dominique Costagliola

series ordinal

1

object named as

Dominique Costagliola

1 reference

22 August 2017

3

Murielle Mary-Krause

0 references

author name string

Sylvie Lang

series ordinal

2

1 reference

PubMed ID

20521126

22 August 2017

Franck Boccara

series ordinal

4

1 reference

22 August 2017

1 August 2010

1 reference

22 August 2017

Current HIV/AIDS reports

1 reference

22 August 2017

7

1 reference

22 August 2017

3

1 reference

22 August 2017

127-133

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-010-0047-3

22 August 2017

0 references

cites work

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

12 December 2020

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

1 reference

12 December 2020

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

12 December 2020

Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy

1 reference

12 December 2020

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

12 December 2020

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study

1 reference

12 December 2020

Severe premature coronary artery disease with protease inhibitors

1 reference

12 December 2020

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

1 reference

12 December 2020

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

12 December 2020

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

1 reference

12 December 2020

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

1 reference

12 December 2020

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

1 reference

12 December 2020

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients

1 reference

12 December 2020

10.1007/S11904-010-0047-3

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20521126